If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma is finalist for four CPhI pharma awards

    • Aptar Pharma
    Health, Pharmaceuticals, Shows, Associations, Media, Packaging Trade Shows, Events, CPhI, Packaging Awards

    Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, is pleased to announce its Platinum Sponsorship of the CPhI Festival of Pharma, to be held online from October 5-16, 2020. A long-time strategic partner and supporter of CPhI events globally, Aptar Pharma will unveil a new, state-of-the-art interactive booth at this virtual event that captures the essence of an in-person experience during these unprecedented times.

    Enhancing the Virtual Visitor Experience

    Part of their Company Showcase, which will be available to visitors of the event for 12 months, Aptar Pharma’s virtual booth will bring to life why it is the go-to drug delivery partner, unlocking value for customers throughout their product development journey. Rich in content, featuring multi-media videos, brochures, scientific publications and other experiences, Aptar Pharma’s life-like booth will give visitors the opportunity to explore, discover and interact with their broad range of complete product and service solutions, further enhancing the virtual experience.

    Carolyn Penot, Director of Operational Marketing at Aptar Pharma commented: “As a longstanding partner of CPhI, we wanted to show our full support for their new Festival of Pharma digital event and are proud to be a Platinum Sponsor. Aptar Pharma’s virtual experience gives us the opportunity to continue to support our worldwide customers, in the absence of in-person events this year, in a new and engaging way.”

    Transforming Ideas into Opportunities

    An expert in transforming ideas into opportunities, Aptar Pharma will showcase in 3D its latest range of innovations, including:

    • PureHale® - a portable and ready-to-use drug delivery solution designed for upper respiratory care
    • Connected Add-On Device for metered-dose inhalers (MDIs)
    • Unidose Trainer Device - a pioneering patient onboarding device from Noble, an Aptar Pharma company, that was used for the first and only U.S. FDA-approved nasal rescue treatment for seizure activity, and is based on Aptar Pharma’s UDS device.

    An Essential Industry Partner During COVID-19

    Aptar Pharma has been an essential partner to industry during the COVID-19 pandemic, ensuring the supply of its portfolio of drug delivery solutions that improve and save lives, which is especially important for customers and patients as the pandemic continues to dominate the healthcare environment.

    Discover how Aptar Pharma services can accelerate and derisk drug development and how its proven solutions are enabling the rapid deployment Covid-related vaccines and treatments for customers.

    Recognizing Innovation Excellence

    Aptar Pharma is proud to be a Finalist for four Digital CPhI Pharma Awards at this year’s event:

    • Excellence in Pharma: Drug Delivery Devices - PureHale® Portable Upper Respiratory Device
    • Excellence in Pharma: Packaging - Activ-Blister™ by Aptar CSP Technologies
    • Excellence in Pharma: Packaging - Noble's Unidose Nasal Training Kit for Nayzilam®
    • Excellence in Pharma: Innovation in Response to COVID-19 - ActivShield™ by Aptar CSP Technologies.

    The winners of the Digital CPhI Pharma Awards will be announced during a live online ceremony on 13 October at 16:00 (CET).

    Sharing Expertise with a Global Audience

    As part of the CPhI Festival of Pharma conference program, two Aptar Pharma experts will share critical industry insights and expertise during the two week event:

    On October 6 at 11:00 CET, Aptar Pharma will sponsor “The Future of Drug Delivery” Keynote Speaker webinar on patient-focused drug design, which will be introduced by Tim McLeroy, Executive Director of Marketing and Patient Services at Noble, an Aptar Pharma company. Tim’s presentation will highlight the importance of remote patient training, onboarding and monitoring – which has increased during COVID-19 - for improving patient adherence and outcomes.

    On October 8 at 15:30 CET, Sai Shankar, Vice-President Global Digital Healthcare Systems at Aptar Pharma, will participate in a live panel discussion entitled “Trends in Pharma Packaging, Administration & Drug Delivery Devices”. As part of his panel discussion, Sai will present on the “Increasing Importance of Connected Devices and Digitalization in Post Pandemic R&D”.

    CPhI Festival of Pharma visitors can register to attend these key presentations via the event website.

    Enlarging Access to Global Pharma Expertise

    Thanks to the virtual format at CPhI Festival of Pharma, Aptar Pharma will be providing expanded access to its experts from around the world and across all delivery routes via online meeting slots, which provide an excellent meeting or networking opportunity. Both new and existing customers can book their meetings by visiting the Aptar Pharma Company Showcase.

    Gael Touya, President of Aptar Pharma, commented: “CPhI plays a pivotal role in the global pharma industry, providing the perfect platforms to meet, network and ultimately do business together. This year, we are happy to support CPhI with its Festival of Pharma and are proud to have created a virtual platform that will deliver the highest quality visitor experience and demonstrate to the industry what makes Aptar Pharma the go-to drug delivery expert.”

    The CPhI Festival of Pharma event will bring the global pharma industry together, and expect to welcome over 20,000 attendees and 700+ exhibitors from around the world, offering best in-class networking, learning and sourcing opportunities – from the comfort of the home office.

    Register now at https://www.cphi.com/festival-of-pharma/.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 30 Sep 2020
    • Hits 647